BlackRock Investment Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

BlackRock Investment Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$510K	Buy	104,124 +1,207	+1%	+$7.25K	﹤0.01%	3043
2016 Q3	$797K	Sell	102,917 -4,676	-4%	-$31.5K	﹤0.01%	2808
2016 Q2	$603K	Buy	107,593 +6,259	+6%	+$40K	﹤0.01%	2954
2016 Q1	$545K	Buy	101,334 +1,714	+2%	+$9.96K	﹤0.01%	2864
2015 Q4	$868K	Buy	99,620 +220	+0.2%	+$1.86K	﹤0.01%	2701
2015 Q3	$834K	Sell	99,400 -1,147	-1%	-$18.3K	﹤0.01%	2729
2015 Q2	$1.77M	Buy	100,547 +96,694	+2,510%	+$1.24M	﹤0.01%	2336
2015 Q1	$45K	Buy	3,853 +58	+2%	+$671	﹤0.01%	3338
2014 Q4	$38K	Sell	3,795 -150	-4%	-$760	﹤0.01%	3375
2014 Q3	$18K	Buy	3,945 +186	+5%	+$999	﹤0.01%	3453
2014 Q2	$25K	Buy	+3,759	New	+$28.3K	﹤0.01%	3354

Other funds holding SRNE

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock Investment Management's SRNE Position: Q4 2016 in Review

BlackRock Investment Management increased its Sorrento Therapeutics, Inc. (SRNE) stake by 1.2% in Q4 2016, buying an estimated $7.25K and bringing the position to 104,124 shares worth $510K. The position accounts for ﹤0.01% of the portfolio, ranked #3043.

BlackRock Investment Management first reported a position in SRNE in Q2 2014 and has held it in 11 quarters since. The position peaked at $1.77M in Q2 2015. 68 funds tracked by Wall St. Rank hold SRNE as of Q4 2016.

BlackRock Investment Management held 104,124 shares of Sorrento Therapeutics, Inc. worth $510K as of Q4 2016.
BlackRock Investment Management bought 1,207 Sorrento Therapeutics, Inc. shares in Q4 2016, an estimated $7.25K.
Sorrento Therapeutics, Inc. made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3043 holding.
BlackRock Investment Management first reported a position in Sorrento Therapeutics, Inc. in Q2 2014 and has held it in 11 quarters since.
BlackRock Investment Management's Sorrento Therapeutics, Inc. position peaked at $1.77M in Q2 2015.
68 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.